NAFLD
Conditions
Interventions
Gold Standard:Liver biopsy was performed, and NAS scoring criteria were based on the guidelines of the National Institutes of Health NASH Clinical Research Network Pathology Working Group.
Index test:A diagnostic model based on demographic and sociological factors, routine blood and liver function test indicators, liver stiffness values from elastography, and serum mass spectrometry dat
Sponsors
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. Gender, age, height, weight, blood pressure, triglyceride (TG), total cholesterol (TC), low-denasity lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), fasting plasma glucose (FPG), and alanine Patients with complete clinical data such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), uric acid (UA), creatinine (Cr), urine nitrogen (BUN), and imaging. 3. Voluntarily participate in this project and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Does not meet the corresponding diagnostic criteria; 2. Combined use of the following drugs: tamoxifen, glucocorticoids, benzodiazepines, amiodarone, methotrexate, sodium valproate; 3. Alcoholic liver disease, viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, hepatolenticular degeneration, total parenteral nutrition and other specific liver diseases that can lead to fatty liver; 4. Inflammatory bowel disease, celiac disease, hypothyroidism, Cushing's syndrome, ß-lipoproteinemia, lipoatrophic diabetes, Mauriac syndrome and other special conditions leading to fatty liver; 5. Liver transplantation patients; 6. Combined with end-stage diseases or malignant tumors; 7. Taking antiviral drugs, hepatoprotective drugs or other liver damage drugs in the past half a year; 8. Patients with important organ dysfunction; 9. Lactating women, pregnant women and minors; 10. Other vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, and illiterates.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The area under the receiver operating characteristic curve;Accuracy;sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactLiang Xiao
Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed